Last week, the Centers for Medicare & Medicaid Services said it will not go ahead with a plan from the Biden administration ...

Novo Nordisk joined the many pharmaceutical companies pushing back on government-negotiated drug pricing in the United States.

The decision is a setback for GLP-1 drugmakers, though it's not entirely surprising given the Trump administration’s focus on curbing government spending.

The U.S. announced an increase in Medicare Advantage payment rates for 2026, exceeding expectations and affecting insurer ...

Medicare Advantage updates while halting proposed anti-obesity drug coverage, impacting millions of potential beneficiaries.

Pa., said Mounjaro changed his life with 'significant' health benefits. He's calling for widespread access to GLP-1 ...

After massive gains in the past five years on the heels of the weight loss blockbuster Zepbound, Eli Lilly & Co (LLY) stock ...

A U.S. senator said a GLP-1 drug changed his life — and now he’s calling for widespread access to anti-obesity medications.

U.S. President Donald Trump late on Tuesday reiterated he would impose tariffs on imports of pharmaceutical products that ...

A legal effort could upend a nearly 40-year program that compensates people who say they were injured by vaccines.

The Trump administration reversed a Biden-era proposal for Medicare coverage of anti-obesity treatments. But on Monday, HHS suggested it is open to future policy considerations toward this end.